Prof. Simon Croft, born in England 8 July 1950, in 1977 got hi PhD degree with a thesis entitled "A Study of Leishmania hertigi". Actually he is Reader in Parasitology at the Department of Infectious and Tropical Diseases at the London School of Hygiene & Tropical Medicine in London. Prof. Croft is a research scientist with a broad background in chemotherapy of tropical diseases. For drug discovery research programme I have developed an international network of collaborators – chemists, structural biologists, biochemists and pharmacists. This approach has involved working with international organisations, the pharmaceutical industry, public-private partnerships and institutes in Africa, Asia and South America. He has project management, presentation and team management skills and many good interactions with scientists from different disciplines around the world. His current research interest is focused on:
Other research programmes collaborators in Europe and USA on antiprotozoal bisphosphonates, FTI inhibitors, topical formulations for parasitic diseases.
- Primary objectives are the identification, evaluation and development of drugs for malaria, leishmaniasis and the trypanosomiases.
- Current support from WHO/TDR, WRAIR USA, the Gates Foundation and MMV has led to the establishment of an international network of scientists and pharmaceutical/biotechnology companies linked to research at the LSHTM
- Involved in four public-private partnerships, with GSK (via MMV), with Bayer (via MMV), with ImmTech Inc. , USA (via Gates) and Zentaris, Germany (via EC grant).
- Research has led to the identification of miltefosine for the treatment of visceral leishmaniasis, recently registered in India, the use of AmBisome for viceral leishmaniasis and a paromomycin ointment for cutaneous leishmaniasis.
His Scientific activity focuses on:
- Development of a European network of scientists for chemotherapy of protozoal diseases through two EC supported COST Actions, joint projects and British Council links.
- Established contacts with biotechnology and bio-seed fund groups in London.
- Advisor to WHO/TDR drug discovery, drug development and clinical committees.
- Section editor on antiparasitic chemotherapy of three review journals.
Head of Electron Microscopy and Histopathology Services (1987 - present)
Department Research Degree Director (Medical Parasitology) (1994 - 1997)
Head of Biochemistry and Chemotherapy Unit (Medical Parasitology) (1996 - 1997)
Research Degree Co-ordinator (School) (1998 - 2000)
Chair, Board of Examiners for Distant Learning MSc Infectious Diseases (2002-)
Membership of Scientific Advisory Bodies
ECCLS (European Committee for Clinical Laboratory Standards), 1988-1989.
Temporary Adviser to WHO/TDR Drug Discovery and Development Groups for African Trypanosomiasis, Leishmaniasis, Chagas' Disease, Malaria, 1991- present
EC COST: COST 815, “Antiparasitic Chemotherapy”, UK Member, 1993 - 1997.
COST B9, “Chemotherapy of Protozoal Infections”, Vice Chairman, UK Member, 1997 - 2002
EC DGXII: INCO-DC and FP5 Proposal Evaluation Panels, 1996 and 1999
NATO Science for Stability Programme, Advisor on Liposome Project, 1994-1999.
MRC, UK Advisory Board (2000-2003)
Oxford Natural Products, Oxford,UK and 4SC, Martinsreid, Germany 2002-2003
International Research Co-ordinator:
- UK Co-ordinator of British Council -Alliance Link with ICSN, CNRS, Gif-sur-Yvette, France [Mechanisms of action of Antileishmanials] . 1994-1996
- UK Co-ordinator British Council Academic Link, Department of Medical Parasitology, LSHTM with Department of Biochemistry, University of Nairobi [Biochemistry of Protozoan parasites]. 1995-1998
- UK Co-ordinator British Council Academic Link “Antimalarial and Antileishmanial Drugs” with National Centre for Cell Biology, Pune, India, 2001-2005
- Current research programmes on antimalarial, antileishmanial and antitrypanosomal drug identification, evaluation and devlopment are supported by WHO/TDR, MMV and Gates Foundation. Other projects on miltefosine for leishmaniasis and drug resistance in leishmaniasis are supported by EC FP5 and on topical formulations for cutaneous leishmaniasis by the Sir Halley Stewart Trust.